​

Ligand Pharmaceuticals (LGND) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LGND Stock Forecast

Ligand Pharmaceuticals (LGND) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $342.00, with a high of $358.00 and a low of $326.00. This represents a 14.38% increase from the last price of $299.00.

$150 $200 $250 $300 $350 $400 High: $358 Avg: $342 Low: $326 Last Closed Price: $299

LGND Stock Rating

Ligand Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (72.22%), 4 Hold (22.22%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 1 4 13 Strong Sell Sell Hold Buy Strong Buy

LGND Price Target Upside V Benchmarks

TypeNameUpside
StockLigand Pharmaceuticals14.38%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1417
Avg Price Target$350.00$345.75$291.76
Last Closing Price$299.00$299.00$299.00
Upside/Downside17.06%15.64%-2.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2638---11
Oct, 2638---11
Sep, 2628---10
Aug, 2627---9
Jul, 2627---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2026Annabel SamimyStifel Nicolaus$350.00$317.3310.30%17.06%
Sep 25, 2026Glen SantangeloBarclays$345.00$299.0415.37%15.38%
Aug 14, 2026Leerink Partners$330.00$290.1013.75%10.37%
Aug 06, 2026Joseph PantginisH.C. Wainwright$358.00$313.5514.18%19.73%
Aug 03, 2026Leland GershellOppenheimer$326.00$287.5413.38%9.03%
Jul 20, 2026Matt HewittCraig-Hallum$345.00$303.0313.85%15.38%
Jul 15, 2026RBC Capital$340.00$300.9712.97%13.71%
Jul 08, 2026Annabel SamimyStifel Nicolaus$332.00$319.433.94%11.04%
Apr 30, 2026Joseph PantginisH.C. Wainwright$289.00$224.8628.52%-3.34%
Apr 28, 2026RBC Capital$252.00$241.794.22%-15.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 25, 2026BarclaysOverweightOverweightinitialise
Sep 23, 2026CitigroupBuyBuyhold
Aug 12, 2026CitigroupBuyBuyhold
Aug 06, 2026H.C. WainwrightBuyBuyhold
Aug 03, 2026OppenheimerOutperformOutperformhold
Jul 20, 2026Craig-HallumBuyBuyhold
Jul 16, 2026BenchmarkBuyBuyhold
Jul 15, 2026RBC CapitalOutperformOutperformhold
Jul 09, 2026Bank of America SecuritiesBuyBuyhold
Apr 28, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.46$-1.98$3.02$-0.22$6.44---
Avg Forecast$3.87$2.79$5.35$5.66$6.07$6.78$7.72$8.54
High Forecast$4.25$2.85$5.47$6.80$7.57$7.17$7.90$8.74
Low Forecast$3.59$2.64$4.97$3.47$4.97$6.40$7.17$7.93
Surprise %-10.59%-170.97%-43.55%-103.89%6.10%---

Revenue Forecast

$100M $150M $200M $250M $300M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$241.54M$196.25M$131.31M$167.13M$268.09M---
Avg Forecast$269.76M$203.95M$128.89M$163.37M$187.13M$225.03M$262.60M$302.00M
High Forecast$290.66M$207.04M$129.19M$163.82M$187.65M$226.62M$263.92M$307.38M
Low Forecast$255.22M$195.53M$128.58M$162.49M$186.43M$223.45M$261.28M$285.48M
Surprise %-10.46%-3.78%1.88%2.31%43.26%---

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$57.14M$-33.36M$52.15M$-4.03M$124.45M---
Avg Forecast$51.75M$26.46M$53.82M$91.14M$111.34M$120.52M$133.80M$151.64M
High Forecast$63.33M$40.01M$85.52M$120.75M$134.42M$127.40M$140.26M$155.16M
Low Forecast$40.17M$12.92M$22.12M$61.53M$88.26M$113.64M$127.34M$140.86M
Surprise %10.42%-226.06%-3.09%-104.42%11.78%---

LGND Forecast FAQ

Is Ligand Pharmaceuticals stock a buy?

Ligand Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Ligand Pharmaceuticals is a favorable investment for most analysts.

What is Ligand Pharmaceuticals's price target?

Ligand Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $342 over the next 12 months. The price target range spans from $326 at the low end to $358 at the high end, suggesting a potential 14.38% change from the previous closing price of $299.

How does Ligand Pharmaceuticals stock forecast compare to its benchmarks?

Ligand Pharmaceuticals's stock forecast shows a 14.38% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ligand Pharmaceuticals over the past three months?

  • November 2026: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ligand Pharmaceuticals’s EPS forecast?

Ligand Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $6.78, marking a 5.28% increase from the reported $6.44 in 2025. Estimates for the following years are $7.72 in 2027, and $8.54 in 2028.

What is Ligand Pharmaceuticals’s revenue forecast?

Ligand Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $225.03M, reflecting a -16.06% decrease from the reported $268.09M in 2025. The forecast for 2027 is $262.6M, and $302M for 2028.

What is Ligand Pharmaceuticals’s net income forecast?

Ligand Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $120.52M, representing a -3.16% decrease from the reported $124.45M in 2025. Projections indicate $133.8M in 2027, and $151.64M in 2028.